Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 0 / 964.784K |
Day Range | - - - |
52 Wk Range | 45.500 - 84.890 |
Market Cap | $7.599B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 53 |
Short Interest | 3.77% |
Days to Cover | 5.55 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Intra-Cellular Therapies (NASDAQ: ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Cantor Fitzgerald on Wednesday, April 24, 2024. The analyst firm set a price target for 120.00 expecting ITCI to rise to within 12 months (a possible 66.37% upside). 38 analyst firms have reported ratings in the last year.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $72.13 last updated April 25, 2024 at 4:20 PM EDT.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q1 earnings are confirmed for Friday, May 10, 2024.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.